公开(公告)号：WO2010031138A2

公开(公告)日：2010-03-25

申请号：PCT/AU2009/001246

申请日：2009-09-18

Applicant: CORBETT RESEARCH PTY LTD ,  REJA, Valin ,  KWOK, Alister ,  STONE, Glenn

Inventor： REJA, Valin ,  KWOK, Alister ,  STONE, Glenn

IPC: G06Q50/00 ,  G01N25/04 ,  G06F19/00 ,  G06N3/02

CPC classification number: G06F19/24 ,  C12Q1/6816 ,  G06F19/20 ,  C12Q2527/107 ,  C12Q2537/165 ,  C12Q2539/101

公开(公告)号：WO2010012086A1

公开(公告)日：2010-02-04

申请号：PCT/CA2009/001055

申请日：2009-07-28

Applicant: GENENEWS CORPORATION ,  LIEW, Choong-Chin ,  MA, Jun ,  GO, Alan, S.

Inventor： LIEW, Choong-Chin ,  MA, Jun ,  GO, Alan, S.

IPC: C12Q1/68 ,  C40B30/00 ,  C40B30/02

CPC classification number: C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/158 ,  G06F19/18 ,  G06F19/20

Abstract: The application provides methods of determining the severity or monitoring the progression of heart failure in a human test subject by determining the level of RNA encoded by one or more heart failure markers genes in the blood of the test patients compared to controls. A kit comprising primers for genes differentially expressed in heart failure is also taught.

Abstract translation: 该应用提供了通过测定与对照相比，测试患者的血液中一种或多种心力衰竭标记基因编码的RNA水平在人类测试受试者中确定严重程度或监测心力衰竭进展的方法。 还教导了包含用于在心力衰竭中差异表达的基因的引物的试剂盒。

公开(公告)号：WO2010003773A1

公开(公告)日：2010-01-14

申请号：PCT/EP2009/057426

申请日：2009-06-16

Applicant: SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS GMBH ,  GEHRMANN, Mathias ,  KRONENWETT, Ralf ,  STROPP, Udo ,  WEBER, Karsten ,  VON TÖRNE, Christian

Inventor： GEHRMANN, Mathias ,  KRONENWETT, Ralf ,  STROPP, Udo ,  WEBER, Karsten ,  VON TÖRNE, Christian

IPC: G06F19/00 ,  C12Q1/68

CPC classification number: G06F19/24 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G06F19/18 ,  G06F19/20

Abstract: The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CA12, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.

Abstract translation: 本发明涉及用于预测患有癌症的患者的癌症结果的方法，所述患者先前被诊断为淋巴结阳性并用细胞毒性化疗治疗，所述方法包括在来自所述患者的生物样品中确定多个的表达水平 选自ACTG1，CA12，CALM2，CCND1，CHPT1，CLEC2B，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3， KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C及VEGF; ABCB1，ABCG2，ADAM15，AKR1C1，AKR1C3，AKT1，BANF1，BCL2，BIRC5，BRMS1，CASP10，CCNE2，CENPJ，CHPT1，EGFR，CTTN，ERBB3，ERBB4，FBLN1，FIP1L1，FLT1，FLT4，FNTA，GATA3，GSTP1， Herbatin，IGF1R，IGHM，KDR，KIT，CKRT5，SLC39A6，MAPK3，MAPT，MKI67，MMP7，MTA1，FRAP1，MUC1，MYC，NCOA3，NFIB，OLFM1，TP53，PCNA，PI3K，PPERLD1，RAB31，RAD54B，RAF1， SCUBE2，STAU，TINF2，TMSL8，VGLL1，TRA @，TUBA1，TUBB，TUBB2A。

公开(公告)号：WO2009132257A3

公开(公告)日：2010-01-07

申请号：PCT/US2009041642

申请日：2009-04-24

Applicant: INTEGRATED BIOSCIENCE SOLUTION ,  RALPH DAVID A ,  O'DOWD GERALD J

Inventor： RALPH DAVID A ,  O'DOWD GERALD J

IPC: C12Q1/00 ,  G01N33/48

CPC classification number: C12Q1/6809 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  G06F19/20

Abstract: The present invention relates to methods for diagnostics, detection or research analysis of cancer. In particular, the present invention is in the field of analysis of the levels of gene expression in normal or noncancerous cells because of their proximity to cancer cells. The present invention further provides for analysis of the altered gene expression levels in normal or noncancerous cells as an indicator of disease prognosis, staging and grading. The current invention is a means to increase the sensitivity of needle core biopsies to detect the presence of cancer.

Abstract translation: 本发明涉及癌症的诊断，检测或研究分析方法。 特别地，本发明在正常或非癌细胞中基因表达水平的分析领域，因为它们与癌细胞接近。 本发明进一步提供了在正常或非癌细胞中改变的基因表达水平的分析，作为疾病预后，分期和分级的指标。 本发明是提高针芯活组织检测癌症存在的敏感性的手段。

公开(公告)号：WO2009146460A2

公开(公告)日：2009-12-03

申请号：PCT/US2009/045863

申请日：2009-06-01

Applicant: ORDWAY RESEARCH INSTITUTE, INC. ,  GLINSKY, Gennadi, V.

Inventor： GLINSKY, Gennadi, V.

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/172 ,  C12Q2600/178 ,  G06F19/18 ,  G06F19/20 ,  G06F19/22

Abstract: The present invention discloses disease-linked SNPs, microRNAs, and microRNA-targeted mRNAs relevant to the pathogenesis of several major human disorders including, but not limited to, multiple types of cancers, type 2 diabetes, type 1 diabetes, Crohn's disease, coronary artery disease, hypertension, rheumatoid arthritis, bipolar disorder. Also provided are methods for the identification of disease phenotype-defming sets of SNPs, microRNAs, and mRNAs that are defined here as a "consensus disease phenocode" as well as methods of using the information provided by these consensus disease phenocodes for various diagnostic, prognostic, and/or therapeutic applications.

Abstract translation: 本发明公开了与几种主要人类疾病的发病机理相关的疾病连锁的SNP，微小RNA和微RNA靶向mRNA，包括但不限于多种类型的癌症，2型糖尿病，1型糖尿病，克罗恩病，冠状动脉 疾病，高血压，类风湿关节炎，双相情感障碍。 还提供了用于鉴定在这里定义为“共有疾病病毒”的SNP，微小RNA和mRNA的疾病表型定义组的方法以及使用由这些共识疾病鉴定提供的信息用于各种诊断，预后的方法 ，和/或治疗应用。

公开(公告)号：WO2009089521A3

公开(公告)日：2009-10-08

申请号：PCT/US2009030719

申请日：2009-01-12

Applicant: NUVERA BIOSCIENCES INC ,  UNIV TEXAS ,  SYMMANS W FRASER ,  HATZIS CHRISTOS ,  PUSZTAI LAJOS

Inventor： SYMMANS W FRASER ,  HATZIS CHRISTOS ,  PUSZTAI LAJOS

IPC: G01N33/574

CPC classification number: G01N33/57484 ,  G01N2800/52 ,  G01N2800/60 ,  G06F19/20 ,  G06F19/28

Abstract: Embodiments of the invention include methods of evaluating a patient and determining the likelihood of a treatment outcome to one or four categories of residual cancer burden classification.

Abstract translation: 本发明的实施例包括评估患者和确定对一类或四类残余癌症负荷分类的治疗结果的可能性的方法。

公开(公告)号：WO2009117119A1

公开(公告)日：2009-09-24

申请号：PCT/US2009/001730

申请日：2009-03-18

Applicant: INTELLIGENT BIO-SYSTEMS, INC. ,  GORDON, Steven, J. ,  VEATCH, Phillip, A.

Inventor： GORDON, Steven, J. ,  VEATCH, Phillip, A.

IPC: G01N33/48

CPC classification number: C12Q1/6869 ,  C12Q1/6806 ,  C12Q1/6825 ,  G06F19/20 ,  C12Q2527/137 ,  C12Q2525/186 ,  C12Q2525/117 ,  C12Q2565/601 ,  C12Q2563/107 ,  C12Q2537/165

Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

Abstract translation: 本发明提供了方法和组合物，包括但不限于使用例如通过合成方法的测序获得的数据来确定核苷酸序列中核酸的身份的算法，计算机可读介质，计算机程序，装置和系统。 本发明的方法包括校正核苷酸测序期间遇到的一种或多种现象，例如通过合成方法进行测序。 这些现象包括但不限于序列引导，序列滞后，光谱串扰以及由照明和/或滤波器响应变化引起的噪声。

公开(公告)号：WO2008115497A3

公开(公告)日：2009-05-28

申请号：PCT/US2008003547

申请日：2008-03-17

Applicant: GENE SECURITY NETWORK ,  RABINOWITZ MATTHEW ,  SWEETKIND-SINGER JOSH ,  BANJEVIC MILENA ,  JOHNSON DAVID SCOTT ,  KIJACIC DUSAN ,  PETROV DIMITRI ,  XU JING ,  DEMKO ZACHARY P

Inventor： RABINOWITZ MATTHEW ,  SWEETKIND-SINGER JOSH ,  BANJEVIC MILENA ,  JOHNSON DAVID SCOTT ,  KIJACIC DUSAN ,  PETROV DIMITRI ,  XU JING ,  DEMKO ZACHARY P

IPC: G06F19/18 ,  G06F19/20 ,  G06F19/22 ,  G06F19/24

CPC classification number: G06F19/22 ,  G06F19/18 ,  G06F19/20 ,  G06F19/24

Abstract: Disclosed herein is a system and method for increasing the fidelity of measured genetic data, for making allele calls, and for determining the state of aneuploidy, in one or a small set of cells, or from fragmentary DNA, where a limited quantity of genetic data is available. Genetic material from the target individual is acquired, amplified and the genetic data is measured using known methods. Poorly or incorrectly measured base pairs, missing alleles and missing regions are reconstructed using expected similarities between the target genome and the genome of genetically related individuals. In accordance with one embodiment of the invention, incomplete genetic data from an embryonic cell are reconstructed at a plurality of loci using the more complete genetic data from a larger sample of diploid cells from one or both parents, with or without haploid genetic data from one or both parents. In another embodiment of the invention, the chromosome copy number can be determined from the measured genetic data of a single or small number of cells, with or without genetic information from one or both parents. In another embodiment of the invention, these determinations are made for the purpose of embryo selection in the context of in-vitro fertilization. In another embodiment of the invention, the genetic data can be reconstructed for the purposes of making phenotypic predictions.

Abstract translation: 本文公开了一种系统和方法，用于增加测量的遗传数据的保真度，进行等位基因调用，并确定在一组或一组细胞中或从片段DNA中确定非整倍体的状态，其中有限数量的遗传数据 是可用的 获取，扩增来自目标个体的遗传物质，并使用已知方法测量遗传数据。 使用目标基因组与遗传相关个体的基因组之间的预期相似性来重建差或不正确测量的碱基对，缺失的等位基因和缺失区域。 根据本发明的一个实施方案，使用来自一个或两个亲本的二倍体细胞的较大样本的更完整的遗传数据，在多个基因座重建来自胚胎细胞的不完全遗传数据，具有或不具有来自一个的单倍体遗传数据 或双亲。 在本发明的另一个实施方案中，染色体拷贝数可以从单个或少数细胞的测量的遗传数据确定，具有或不具有来自一个或两个亲本的遗传信息。 在本发明的另一个实施方案中，这些确定是为了在体外受精的背景下进行胚胎选择的目的。 在本发明的另一个实施方案中，为了进行表型预测的目的，可以重建遗传数据。

公开(公告)号：WO2009062184A1

公开(公告)日：2009-05-14

申请号：PCT/US2008/083041

申请日：2008-11-10

Applicant: IVERSON GENETIC DIAGNOSTICS, INC. ,  SPROLES, Dean, I. ,  SWANK, Roy, L.

Inventor： SPROLES, Dean, I. ,  SWANK, Roy, L.

IPC: G06F19/00

CPC classification number: G06F19/18 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G06F19/20 ,  G06F19/28

Abstract: Broad-based gene association transcript test for multiple sclerosis and data structure. Multiple sclerosis considerations for this unique test include a custom set of genetic sequences associated in peer-reviewed literature with various known multiple sclerosis related to exposure to toxic substances. Such multiple sclerosis symptoms include specific genetic expressions linked to symptoms of the disease. The base dataset may be developed through clinical samples obtained by third-parties. Online access of real-time phenotype/genotype associative testing for physicians and patients may be promoted through an analysis of a customized microarray testing service.

Abstract translation: 基于广泛的基因关联转录检测多发性硬化和数据结构。 针对这种独特测试的多发性硬化症考虑包括与同行评议的文献相关的一系列遗传序列，其中包括与暴露于有毒物质相关的各种已知的多发性硬化症。 这种多发性硬化症状包括与疾病症状相关的特异性遗传表达。 基础数据集可以通过第三方获得的临床样本来开发。 可以通过分析定制的微阵列测试服务来促进医生和患者的实时表型/基因型联合检测的在线访问。

公开(公告)号：WO2009062180A1

公开(公告)日：2009-05-14

申请号：PCT/US2008/083036

申请日：2008-11-10

Applicant: IVERSON GENETIC DIAGNOSTICS, INC. ,  SPROLES, Dean, I.

Inventor： SPROLES, Dean, I.

IPC: G06F19/00

CPC classification number: G06F19/28 ,  G06F19/20

Abstract: Broad-based genetic mutation association gene transcript test and data structure. Genetic mutation considerations for this unique test include a custom set of genetic sequences associated in peer-reviewed literature with various known genetic mutation related to exposure to toxic substances. Such genetic mutations include specific gene sequence alterations based on exposure to diesel fuel, aviation fuel, jet fuel, and many other toxic substances often needed in the aviation and refining industries. The base dataset may be developed through clinical samples obtained by third-parties. Online access of real-time phenotype/genotype associative testing for physicians and patients may be promoted through an analysis of a customized microarray testing service.

Abstract translation: 基于广泛的遗传突变关联基因转录检测和数据结构。 该独特测试的遗传突变考虑包括与同行评议的文献相关的一系列遗传序列，其具有与暴露于有毒物质相关的各种已知遗传突变。 这种基因突变包括基于暴露于柴油燃料，航空燃料，喷气燃料以及航空和精炼行业通常需要的许多其它有毒物质的特定基因序列变化。 基础数据集可以通过第三方获得的临床样本来开发。 可以通过分析定制的微阵列测试服务来促进医生和患者的实时表型/基因型联合检测的在线访问。